Oncology Business Management | Specialty

In a Surprise Finding, Gene Mutation Found Linked to Low-Risk Bladder Cancer

October 16th 2013

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability

October 15th 2013

Additional investment in and collaboration with ADC Therapeutics

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

October 14th 2013

Traditionally, payers have been increasingly more proactive in their management of drug expenditures in cancers with the highest prevalence and with the more costly therapeutics.

Researchers identify four genetic variants that are linked to esophageal cancer and its precursor, Barrett's esophagus

October 14th 2013

Findings from the first large-scale, genome-wide association study of esophageal adenocarcinoma may lead to new screening tools for those at high risk.

Leveraging Health Reform to Combat a History of Cancer

October 11th 2013

Governor Steve Beshear did not sugarcoat the data on May 9, 2013, when he said Kentucky would take an offer it couldn't refuse. With his state ranked worst in the nation in smoking and cancer deaths, and not far behind in heart disease, Beshear was "tired of being at the bottom."

Does Good Cholesterol Increase Breast Cancer Risk?

October 10th 2013

A protein receptor for the "good cholesterol," HDL, may help make breast cancer more aggressive and offer a new target for treating the disease.

When More Medicine Isn't Always Better: Penn Study Reveals High Costs of Unnecessary Radiation Treatments for Terminal Cancer Patients

October 9th 2013

More than 95 Percent of Advanced Prostate Cancer Patients Receive Multiple Radiation Treatments for Pain Control, Despite Evidence Pointing to Equal Benefit from Single Treatments

Association of Community Cancer Centers' 2013 Innovator Award Recipients Take Spotlight at National Oncology Conference

October 8th 2013

Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers' 2013 Innovator Awards.

National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million

October 7th 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

Free Head, Neck Cancer Screenings Have Positive Impact in Urban Areas

October 4th 2013

Offering free head and neck cancer screenings annually to the community not only has the possibility of early detection, but also the opportunity – particularly in an urban city – to increase a person's understanding of risk factors that cause cancer, according to a new study from Henry Ford Hospital in Detroit.

ACCC Institute Calls for Collaboration, Adaptation to Maximize Patient Care Delivery amid Consolidation

October 4th 2013

In response to the growing trend of hospital consolidation, including questions about cancer care decision-making, cost impacts, and delivery of care, the ACCC Institute for the Future of Oncology has released a new white paper that provides perspectives on how these alignments are affecting cancer care providers, cancer programs, and the patients they serve.

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Merrimack Pharmaceuticals Completes Enrollment of Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

October 3rd 2013

Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.

The State of Oncology Practice: A Discussion With Anupama Kurup Acheson, MD

October 2nd 2013

Increasing financial and administrative pressures-exacerbated by the federal sequester and continued rollout of the Affordable Care Act-have created instability and uncertainty for oncology practices nationwide.

Dr. Hudis on BOLERO-3 Trial Biomarker Observations

October 1st 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus

October 1st 2013

Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.

FDA Approves Neoadjuvant Pertuzumab Regimen

September 30th 2013

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

Personalized Medicine in Colorectal Cancer

September 29th 2013

Novel Therapies in Development for mCRC

September 29th 2013

Second-Line and Salvage Treatment of mCRC

September 29th 2013